Doctor of Medicine, Chief Physician, supported by the Beijing Outstanding Talent Training Program for Young Backbone. Currently serving as Deputy Director (presiding over work) of the First Ward of the Gastrointestinal Tumor Center at Peking University Cancer Hospital. Concurrently holds positions as Member and Secretary of the Gastric Cancer Quality Control Expert Committee of the National Cancer Quality Control Center, Executive Director of the Youth Council of the Chinese Anti-Cancer Association, Member of the Gastric Cancer Professional Committee of the Chinese Anti-Cancer Association, Executive Committee Member and Secretary-General of the Surgical Safety and Quality Control Special Committee of the Chinese Anti-Cancer Association, Executive Committee Member of the Tumor Big Data and Real-World Research Special Committee of the Chinese Anti-Cancer Association, Youth Member of the Chinese Society of Clinical Oncology, and Member of the International Gastric Cancer Association. Primary research directions include minimally invasive surgery and perioperative comprehensive treatment for gastric cancer, as well as the development and application of methodological frameworks for surgical clinical research. Possesses extensive experience in data-driven clinical practices, including analysis of surgical video data, construction and quality control of gastric cancer-specific disease databases. Has published over 120 academic articles in important journals in the field, such as *Nature Medicine*, *JAMA Surgery*, and *Gastric Cancer*. Published papers have been cited over 1,970 times on Google Scholar (h-index 24). Holds 4 authorized national invention patents. **Representative Achievements** 1. **Randomized controlled trial of laparoscopic surgery after chemotherapy for gastric cancer**: This is the first global randomized controlled trial in this field, demonstrating that for patients with advanced gastric cancer after neoadjuvant therapy, laparoscopic surgery can effectively reduce postoperative pain, lower postoperative complications by 26% (20% vs. 46%), and improve tolerance to adjuvant chemotherapy. (*JAMA Surgery*, 2019) 2. **Development of a computer vision-based surgical quality assessment tool**: Using laparoscopic gastric cancer surgery as an entry point, first developed a subjective assessment tool for laparoscopic gastric cancer surgical quality and a tool for annotating surgical phases and events in gastric cancer surgery. Initially established a subjective assessment dataset for laparoscopic gastric cancer surgical quality. Based on this work, conducted preliminary exploration of computer-based assessment methods for laparoscopic gastric cancer surgical quality. Has mastered multiple methods for video feature extraction and temporal model design, proposed partitioning methods based on hard sample mining and reinforcement learning methods, and designed an unsupervised segmentation method for surgical instruments and an objective surgical quality assessment model based on the surgical field. Early experimental results have demonstrated the promising potential of this approach, and have been invited multiple times for oral presentations at top academic conferences in computer vision. Obtained 1 authorized national invention patent. (*MICCAI 2019*, *MICCAI 2020*, *CVPR 2021*) 3. **First-line study of PD-1/CTLA-4 bispecific antibody combined with chemotherapy for advanced gastric cancer**: This study utilized the domestically developed innovative drug cadonilimab to conduct the first international clinical study of PD-1/CTLA-4 bispecific antibody combined with chemotherapy as first-line treatment for advanced gastric cancer. It demonstrated that this regimen has good safety and efficacy, significantly prolonging patient survival. The publication of the study results provided strong support for the approval of cadonilimab as a first-line treatment indication for advanced gastric cancer. (*Nature Medicine*, 2024)